Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
This study has been completed.
Sponsor:
Stanford University
Collaborators:
Amgen
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00398372
First received: November 9, 2006
Last updated: May 31, 2011
Last verified: July 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.
| Condition | Intervention |
|---|---|
|
Lymphoma, Non-Hodgkin Lymphomas: Non-Hodgkin Lymphomas: Non-Hodgkin Cutaneous Lymphoma Lymphomas: Non-Hodgkin Diffuse Large B-Cell Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell Lymphomas: Non-Hodgkin Mantle Cell Lymphomas: Non-Hodgkin Marginal Zone Lymphomas: Non-Hodgkin Peripheral T-Cell Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia |
Drug: Rituximab Drug: Epratuzumab |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label |
| Official Title: | Le20: Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment |
Resource links provided by NLM:
Further study details as provided by Stanford University:
Primary Outcome Measures:
- To characterize the molecular and cell biology of the tumor cells in lymphoma. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 500 |
| Study Start Date: | November 2000 |
| Study Completion Date: | September 2009 |
| Primary Completion Date: | June 2007 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00398372
Locations
| United States, California | |
| Stanford University School of Medicine | |
| Stanford, California, United States, 94305 | |
Sponsors and Collaborators
Stanford University
Amgen
Investigators
| Principal Investigator: | Wen-Kai Weng | Stanford University |
More Information
No publications provided
| Responsible Party: | Wen-Kai Weng, Stanford University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT00398372 History of Changes |
| Other Study ID Numbers: | LYMNHL0031, 200114861, 77550, CA09287, CA111827, LYMNHL0031 |
| Study First Received: | November 9, 2006 |
| Last Updated: | May 31, 2011 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Lymphoma Lymphoma, Non-Hodgkin Waldenstrom Macroglobulinemia Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Neoplasms, Plasma Cell Hemostatic Disorders Vascular Diseases |
Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Rituximab Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions Antirheumatic Agents Therapeutic Uses Antineoplastic Agents |
ClinicalTrials.gov processed this record on June 17, 2013